CN1485056A - Medication for bronchial asthma and chronic bronchitis , and its preparation method - Google Patents
Medication for bronchial asthma and chronic bronchitis , and its preparation method Download PDFInfo
- Publication number
- CN1485056A CN1485056A CNA02130775XA CN02130775A CN1485056A CN 1485056 A CN1485056 A CN 1485056A CN A02130775X A CNA02130775X A CN A02130775XA CN 02130775 A CN02130775 A CN 02130775A CN 1485056 A CN1485056 A CN 1485056A
- Authority
- CN
- China
- Prior art keywords
- weight portions
- medicine
- treatment
- bronchial asthma
- crude drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
A chinese medicine for treating bronchial asthma, acute and chronic abronchitis without adverse effect. The raw material comprises (by weight): Japanese yam1000-2000, herb of remote lemongrass1000-2000, magnolia bark500-1500. The preparation method comprises, extracting effective components from each material, mixing and extracting, then obtaining various formulations, such as pill, capsule, tablet, oral liquid or injector.
Description
Technical field
The present invention relates to a kind of treatment bronchial asthma and acute and chronic bronchitis drug matching and preparation method.
At present, treatment doctor trained in Western medicine for asthma mainly is the control acute attack, comprise adrenin, theophylline, the cholinolytic class, multiple medicine such as glucocorticoid is independent or unite use to reach the purpose of rapid alleviation bronchospasm, the treatment of acute episode of chronic bronchitis and chronic persistence mainly based on infection, go expectorant, antitussive, when panting, use the identical medicine of bronchial asthma could obtain clinical efficacy preferably, but the life-time service said medicine can produce some severe complications; There is asthmatic patient 1.5 hundred million in the whole world at present, has every year 100000 people to die from asthma, and China's asthmatic patient has surpassed ten million.Because asthma is because of complexity, and individual variation is bigger, Chinese medicine has accumulated many clinical effective prescriptions as " DINGCHUAN TANG ", " Ephedrae Decoction ", " MAXINGSHIGAN TANG " to treatment of asthma, though asthma is had certain therapeutical effect, clinical efficacy is not good enough.
The object of the invention is to provide a kind of treatment bronchial asthma and acute and chronic bronchitis clinical efficacy better, and drug matching that has no side effect and preparation method.
Summary of the invention
The object of the invention can be achieved through the following technical solutions:
The crude drug of medicine of the present invention is: Rhizoma Dioscoreae Nipponicae 1000～2000 weight portions, Herba Cymbopogonis 1000～2000 weight portions, Cortex Magnoliae Officinalis 500～1500 weight portions.
Crude drug preferred proportion of the present invention is: Rhizoma Dioscoreae Nipponicae 1300 weight portions, Herba Cymbopogonis 510 weight portions, Cortex Magnoliae Officinalis 750 weight portions.
The crude drug of medicine of the present invention also can be Rhizoma Dioscoreae Nipponicae 1000～2000 weight portions, Herba Cymbopogonis 1000～2000 weight portions, Cortex Magnoliae Officinalis 500～1500 weight portions, Herba Ephedrae 200～600 weight portions.
Crude drug preferred proportion of the present invention is: Rhizoma Dioscoreae Nipponicae 1300 weight portions, Herba Cymbopogonis 510 weight portions, Cortex Magnoliae Officinalis 750 weight portions, Herba Ephedrae 380 weight portions.
Pharmaceutical preparation of the present invention is for to carry out extracts active ingredients respectively to above single medicinal material, and the united extraction extracting solution through optimizing technology, is made clinical acceptable form of Chinese drug, comprises pill, capsule, granule, tablet, oral liquid or injection etc.
Drug administration amount of the present invention is suitable crude drug amount 35.28 grams every day.
Experimental example 1: imperial fragrant Asthma capsule Pharmacodynamic test of active extract
1 experimental drug
1.1 claimed by the reagent name: star China institute of materia medica, imperial fragrant Asthma capsule (LXP) 980428 Shaanxi
1.2 being subjected to the reagent thing prepares: get the LXP content and add the 5%CMC-Na mixing in right amount respectively, the medicine that is made into same equivalance, variable concentrations is standby.Its leachate of isolated test.
1.3 drug efficacy study solvent: 0.5%CMC-Na
2 route of administration
Adopt the filling stomach method consistent with the clinical administration approach.Capacity is with mice 0.2ml/10g, rat 1.0ml/100g, Cavia porcellus 0.5ml/100g; Dosage is seen each test respectively under one's name.
3 experimental techniques and result
3.1 drawing, histamine-acetylcholine spraying breathes heavily test: the Cavia porcellus of getting 150～200g, put into the fog chamber, constant speed, constant sprayed into 2% acecoline and 0.1% histamine phosphate's mixed liquor 15 seconds, observation causes that animal breath is rapid, the time of tic and tumble, and with the tumble time be the qualified animal of asthma less than 120 seconds animal.The animal that asthma is qualified is divided into 8 groups at random, and 10/group, experimental group gavages LXP 0.2,0.4,0.8g/kg, once a day, and continuous 5 days, after the last administration one hour, with said method, draw the time of breathing heavily vapor recording Cavia porcellus tumble, the results are shown in Table 1.
Table 1, imperial fragrant Asthma capsule content draw the influence of the effect of breathing heavily to histamine-acetylcholine
Suitable crude drug tumble time (X ± SD
s) prolongation %
Group dosage (g/kg) n
After the preceding administration of amount (g/kg) administration
Blank 5ml/kg 10 89.7 ± 14.6 91.6 ± 14.4 2.1
0.2???????1.84??????????10???????87.9±10.1????146.4±31.2
**??????66.6
LXP???0.4???????3.68??????????10???????89.1±13.5????165.0±51.8
**??????85.2
0.8???????7.35??????????10???????88.7±14.1????154.9±18.6
**??????74.6
Compare with the blank group,
*P＜0.01
3.2 lung overflow test: the grouping of Cavia porcellus can be referring to table 2 to drug dose.Lumbar injection 25% urethane (5ml/kg) anesthesia, conventional method is Cavia porcellus and separate trachea fixedly.Tracheal intubation is pressed lung overflow experimental technique connect animal artificial respirator, pressure transducer, monitor.Regulating respiratory frequency 65 times/minute, breathing the time ratio is that 1.5: 1, tidal volume are 11ml.On the Cavia porcellus thoracic wall, open a duck eye, cause pneumothorax, to suppress spontaneous respiration.Separate duodenum, supply with medicinal; Separate jugular vein, for the injection histamine.Trace lung overflow curve, treat that curve stablizes posterior vein and only inject histamine phosphate 5 μ g/, cause tracheospasm, record water surface elevation, lung overflow curve and histamine effect are held time.After treating that curve recovers normal 5min, in the administration of duodenum The initial segment, respectively at after the administration 0,30,60, the quiet notes of 90min are with the dosage histamine phosphate, observe medicine histamine is caused the antagonism of convulsion, the results are shown in Table 2.LXP causes the guinea pig trachea spasm to histamine tangible antagonism, and the lung spillway discharge reduces, and the curve lifting height descends, the histamine effect shortening of holding time.
Table 2, imperial fragrant Asthma capsule content are to the influence of Cavia porcellus overflow
| Dosage group (g/kg) | Suitable crude drug amount (g/kg) | ?? ?? ????n | Liquid level falling head (mm)/curve rising height (mm)/histamine action time (s) X ± SD |
| ????0(min)????????30(min)???????60(min)??????90(min) | |||
| Control group-0.2 LXP 0.4 0.8 | ? ? ? ? ????1.84 ? ? ????3.68 ? ? ????7.35 ? | ? ????6 ? ? ????8 ? ? ????8 ? ? ????6 ? | ????8.5±2.0??????8.8±1.2??????10.0±0.9????9.0±2.2 ????7.7±2.4??????8.7±1.8??????9.7±2.2?????9.3±2.1 ????166±50???????156±30???????155±64??????130±37 ????9.4±0.9??????4.6±0.9**????5.0±0.8**???7.4±2.4 ????8.7±2.3??????5.7±2.7*?????5.5±1.3**???7.4±1.5 ????170±20???????83±15**??????88±23**?????115±15 ????9.3±0.7??????3.8±0.7**????4.5±1.6**???7.0±1.7 ????7.6±1.6??????3.9±1.2**????3.8±2.4**???5.4±1.5** ????168±64???????59±27**??????85±49**?????48±47** ????9.3±1.6??????3.8±1.0**????4.3±1.0**???5.8±1.9* ????8.5±1.6??????3.3±1.5**????3.3±0.6**???4.9±2.5** ????174±45???????56±30**??????64±17**?????99±17 |
Compare * P＜0.05, * * P＜0.01 with matched group
3.3 guinea-pig isolated trachea sheet test: the Cavia porcellus of getting 350～500g, conventional method prepares the guinea-pig isolated trachea sheet, be linked to be one with 3～4, the upper end links to each other with tonotransducer, the lower end is hung on the ventilation hook, place in the maxwell bath pipe that fills 37 ± 0.5 ℃ of Ke of 40ml-Heng Shi liquid, wherein pass to 95%O
2And 5%CO
2, loading is that 2g, per half an hour change one time of nutrition liquid.Behind the balance 2hr, add Ach to final concentration 10 μ g/ml, adding immediately was subjected to reagent thing (medicine and final concentration see Table 3) to observe 5 minutes inner curve height after trachea shrank peaking, and calculated the trachea contraction inhibiting rate according to following formula, asked IC
50, washing then 3～5 times, baseline carries out next dosage or drug test respectively after recovering normally.
Table 3, imperial fragrant Asthma capsule content are to the spasmolysis of isolated tracheal smooth muscle
Group final concentration (g/ml) n suppression ratio (%) IC
50(g/ml)
3.75×10
-3????????6?????????23.9±8.5???????????8.64×10
-3
LXP 7.50 * 10
-36 46.7 ± 12.9 suitable crude drug amounts 7.94 * 10
-2)
1.50×10
-2????????6?????????81.1±8.3
3.4 cough-relieving experiment: (1) white mice SO2 draws and coughs experiment: 30 of white mice, male and female half and half are divided into 3 groups at random by body weight, 10/group.Be respectively: blank group, high, medium and low three the dosage groups of Asthma capsule content,, gastric infusion 5 days (dosage sees Table 4) continuously, airtight 250ml wide mouthed bottle is put in the last administration after 1 hour, injection 4ml SO
2Draw and cough, according to the cough number of times in documentation standards observation and the record 2min.The results are shown in Table 4.LXP obviously reduces SO
2Draw and cough number of times.
Table 4, imperial fragrant Asthma capsule content are to SO
2Draw and cough influence
The 2min number of times of coughing
Group dosage (g/kg) is crude drug amount (g/kg) number of animals (only) quite
( X±SD)
Blank 20ml/kg 10 36.8 ± 9.8
LXP???????0.3???????????2.750????????????????10??????????21.7±9.1**
0.6???????????5.510????????????????10??????????21.5±4.4**
1.2???????????11.03????????????????10??????????19.4±4.2**
Compare * P＜0.05, * * P＜0.01 with the blank group
(2) white mice ammonia draws and coughs experiment: the continuous gastric infusion of white mice 5 days, and the last administration was put into the fog chamber with mice after 1 hour, and ammonia 0.4ml splashes in the beaker of the 500ml on fog chamber's plank with holes, is heated 2 minutes, observes ammonia and draws and coughs number of times, the results are shown in Table 5.
Table 5, imperial fragrant Asthma capsule content draw ammonia coughs influence
The 2min number of times of coughing
Group dosage (g/kg) is crude drug amount (g/kg) number of animals (only) quite
( X±SD)
Blank 20ml/kg 10 56.3 ± 13.0
LXP?????0.3????????????2.75????????????????????10??????????35.4±17.1**
0.6????????????5.51????????????????????10??????????33.6±17.5**
1.2????????????11.03???????????????????10??????????41.7±11.1*
Compare * P＜0.05, * * P＜0.01 with the blank group
3.5 mice carbon clearance speed experiment: the continuous gastric infusion of white mice 5 days, according to document intravenous injection india ink (diluting 4 times) 0.1ml/10g, get blood 25 μ l behind the last administration 1hr respectively at quiet notes back 2min, 10min eye socket, each adds 0.1%Na
2CO
32ml shakes up, and surveys absorbance (OD) at wavelength 600nm place, after last is got blood mice is put to death, and claims liver spleen weight.Be calculated as follows and clean up index K, phagocytic index α, the results are shown in Table 6.The exponential sum of cleaning up that LXP strengthens the white mice carbon powder gulps down and has a liking for index.
Table 6, imperial fragrant Asthma capsule content are to the influence of mice carbon clearance speed
The suitable crude drug amount of dosage
Group
n?????K( X±SD)???????????α( X±SD)
(g/kg)????(g/kg)
Blank 20ml/kg 10 0.0201 ± 0.0125 4.47 ± 1.37
LXP??????????0.3????????2.75?????????10????0.0348±0.0118*?????5.23±1.34
0.0412±0.0176*
0.6????????5.51?????????10????6.19±1.10**
*
1.2????????11.03????????10????0.0352±0.0159*?????5.99±0.78**
Compare * P＜0.05, * * P＜0.01 with the blank group
3.6 anoxia enduring experiment: the continuous gastric infusion of white mice 5 days, behind the last administration 1hr, put into the airtight wide mouthed bottle of the 250ml that the 15g sodica calx is housed according to document, observe and the record death time, the results are shown in Table 7.
Table 7, imperial fragrant Asthma capsule content are to the influence of normal pressure anoxia enduring
The suitable crude drug amount g/kg n death time of group dosage (g/kg) (X ± SDmin)
Blank 20ml/kg 10 28.1 ± 5.0
LXP?????0.3???????????2.75??????????????10????40.9±6.5**
0.6???????????5.51??????????????10????37.7±8.7**
1.2???????????11.03?????????????10????37.8±6.3**
Compare * P＜0.05, * * P＜0.01 with the blank group
4 conclusions
Dragon fragrant Asthma capsule content 0.2,0.4,0.8g/kg (suitable crude drug amount 1.84,3.68,7.35g/kg respectively), gastric infusion can obviously prolong acetylcholine-histamine and draw and breathe heavily falling the time of Cavia porcellus; The lung spillway discharge that obviously reduces anaesthetized guinea pig increases, and lung overflow curve lifting height reduces, and shortens histamine and causes holding time of spasm effect; LXP causes the guinea-pig isolated tracheal smooth muscle spasm to acetylcholine and has obvious relexation; Obvious reduction sulfur dioxide and strong aqua ammonia draw coughs number of times; Mouse stomach LXP 0.3,0.6,1.2g/kg (suitable crude drug amount 2.75,5.51,11.03g/kg respectively) increase mice carbon powder Cl, and same dosage still has anti-hypoxia and certain antifatigue effect; LXP has and significantly relievings asthma and antitussive effect in sum.
Experimental example 2: imperial fragrant Asthma capsule treatment bronchial asthma 34 routine clinical observations
1 diagnostic criteria
1.1 Western medicine diagnose standard: breathe the diagnostic criteria of sick association of system with reference to Chinese Medical Association and draft the bronchial asthma diagnostic criteria with " new Chinese medicine treatment bronchial asthma clinical guidance principle ".
1.2 tcm syndrome standard:, draft " mutual resistance of the expectorant stasis of blood, impairment of dispersing and descending function of the lung " syndrome standard with reference to related content in " the clinical research guideline of new Chinese medicine treatment bronchial asthma " and high Chinese medicine universities and colleges' state-compiled textbooks " Chinese Internal Medicine " " bronchial wheezing ", " the syndrome of dyspnea " chapters and sections.
1.3 clinical symptoms score standard:, formulate clinical symptoms light and heavy degree score standard with reference to related standards in " the clinical research guideline of new Chinese medicine treatment bronchial asthma ".
2 general clinical datas
Doctor trained in Western medicine is clarified a diagnosis and is that bronchial asthma, tcm diagnosis are " asthma or the syndrome of dyspnea ", and dialectical is " mutual resistance of the expectorant stasis of blood, impairment of dispersing and descending function of the lung " syndrome 34 routine patients, wherein, and male's 21 examples, women's 13 examples; 20～65 years old age, 47.6 years old mean age; 2 months～10 years inequalities of the course of disease, average course of disease 68.5 months.
3 Therapeutic Method
2.1 medicine: the fragrant Asthma capsule of medicine dragon of the present invention, each 3～4, three times on the one.Be 4 weeks the course of treatment, carries out the clinical efficacy statistics after finishing the course of treatment.This group case is removed the former adrenocortical hormone of taking of patient and is needed slow decrement and status asthmaticus in the observation of curative effect process, needs outside the emergency aid and treatment, generally need not relevant other drug with this treatment.
2.2 observation index: clinical symptoms change before and after (1) treatment; (2) peripheral hemogram changes before and after the treatment; (3) blood parameters changes before and after the treatment; (4) changes in heart rate before and after the treatment; (5) treatment back untoward reaction.
4 therapeutic outcomes
4.1 the clinical symptoms integration changes before and after the treatment: the results are shown in Table 1.
Clinical symptoms integration variation before and after table 1 treatment (X ± SD)
After the treatment
Before the clinical symptoms treatment
Around the 3rd week of second week first week the
3.54 ± 0.66 2.80 ± 0.79*, 1.17 ± 0.92**, 0.91 ± 0.82*** pants
0.78±0.56***
Rale 3.43 ± 0.67 2.57 ± 0.82*, 1.17 ± 0.89**, 1.83 ± 0.79***
0.83±0.82***
Cough 3.54 ± 0.57 2.69 ± 0.87*, 1.14 ± 0.87** 0.89 ± 0.79***
0.81±0.55***
3.40 ± 0.74 2.77 ± 0.77*, 1.20 ± 0.76**, 1.00 ± 0.79*** coughs up phlegm
0.72±0.55***
Vexed 2.39 ± 0.83 2.23 ± 0.72 2.15 ± 0.70 1.97 ± 0.67* of fullness in the chest and hypochondrium
1.85±0.70*
Distension and fullness in the abdomen 1.98 ± 0.13 1.76 ± 0.54 1.56 ± 0.55 1.17 ± 0.12*
0.95±0.20*
Purple dark 2.23 ± 0.69 2.00 ± 0.82 1.92 ± 0.87 1.67 ± 0.80* of lip and nail
1.08±0.83*
Relatively preceding with treatment, * P＜0.05, material P＜0.01, * * * P＜0.001,
4.2 clinical cardinal symptom onset time: the results are shown in Table 2.
Table 2, clinical cardinal symptom onset time (X ± SD)
Cardinal symptom onset time (h)
Pant 6.38 ± 2.34
Rale 8.20 ± 3.45
Cough 12.32 ± 3.36
Cough up phlegm 15.15 ± 3.17
4.3 peripheral hemogram changes before and after the treatment: find that through the peripheral hemogram inspection of treatment front and back former owing to infect the case that leukocyte raises, leukocyte has to a certain degree decline after treating, compare with matched group, learn by statistics and handle, the existing statistical significance in 2 week backs, P＜0.05, difference has significance.Bronchial asthma often is associated with bacterial infection, often causes that leukocyte raises.This clinical observation illustrates that this medicine has anti-infectious function.Peripheral hemogram the results are shown in Table 3.
Peripheral hemogram variation before and after table 3, the treatment (X ± s)
After the treatment
Before the project treatment
Around the 3rd week of second week first week the
Hemoglobin (g/L) 13.5 ± ± 2.30 13.56 ± 3.11 14.34 ± 2.89 13.56 ± 2.78 13.67 ± 2.19
Leukocyte (* 10
9) 10.6 ± 2.34 9.34 ± 2.15*, 8.56 ± 2.36*, 7.23 ± 2.33**, 7.67 ± 2.18**
Platelet (* 10
9) 146 ± 34.34 136.2 ± 35.4 147.2 ± 24.5 147.4 ± 35.6 145.3 ± 33.1
Relatively preceding with treatment, * P＜0.05, * * P＜0.01
4.4 blood parameters changes before and after the treatment: the results are shown in Table 4.
Blood parameters variation before and after table 4 treatment (X ± SD)
After the treatment
Before the project treatment
Around the 3rd week of second week first week the
UREA(mmol/L)??4.51±1.32????4.64±1.52?????3.34±2.12?????3.56±1.72??????3.67±1.19
ALT(IU/L)?????25.6±12.3????23.3±11.5?????30.5±9.12?????31.4±7.3???????29.7±6.4
AST(IU/L)?????30.3±11.3????29.5±8.5??????28.5±9.22?????33.4±6.7???????29.9±8.6
GLU(mmol/L)???4.05±1.21????3.93±2.1??????3.44±2.12?????3.15±1.35??????3.07±2.16
4.5 changes in heart rate before and after the treatment: the results are shown in Table 5.
Patient's changes in heart rate before and after table 5, the treatment (X ± SD)
Treat preceding 78.2 ± 7.3
After the treatment
First week 78.3 ± 8.2
Second week 85.7 ± 5.2
The 3rd week 89.5 ± 7.3
Around the 84.7 ± 5.6
5 clinical efficacies statistics
5.1 curative effect determinate standard: in " new Chinese medicine clinical research guideline " with reference to the announcement of Ministry of Public Health bureau of drug administration " new Chinese medicine treatment bronchial asthma clinical research guideline ", draft following standard:
(1) clinic control: pant, rale, cough, cough up phlegm and the pulmonary wheezing sound disappears or not enough slight person; Or the symptom integral value reduces by 90%;
(2) produce effects: pant, rale, cough, cough up phlegm and pulmonary's wheezing sound is clearly better, or the symptom integral value reduces by 60%～89%;
(3) effective: as pant, rale, cough, cough up phlegm and pulmonary's wheezing sound takes a turn for the better to some extent, or the symptom integral value to reduce by 30～59%;
(4) invalid: as pant, rale, cough, cough up phlegm and the commentaries on classics of not getting better of pulmonary's wheezing sound, or the symptom integral value to reduce＜30%.
5.2 efficacy result: through pressing clinical efficacy criterion statistics, clinic control 16 examples account for 47.1%, and produce effects 7 examples account for 20.6%, and effective 8 examples account for 23.5%, and invalid 3 examples account for 8.8%.Clinical total obvious effective rate 67.7%, total effective rate 91.2%.
6 conclusions
The fragrant Asthma capsule of dragon can obviously be improved bronchial asthma patient clinical symptoms, to breathe heavily, cough, the improvement of phlegm syndrome shape is more obvious; Clinical total obvious effective rate 67.7%, total effective rate 91.2%; To bronchial asthma concurrent infection patient, imperial fragrant Asthma capsule can reduce the leukocyte of rising, and it has antibacterial and anti-inflammation functions; By before and after the treatment blood samples of patients biochemical indicator testing result being shown, take for a long time patient's heart, liver, renal function are not had obvious influence, show imperial fragrant Asthma capsule clinical drug safety, nontoxic.
Embodiment 1: Rhizoma Dioscoreae Nipponicae 1300 grams, Herba Cymbopogonis 510 grams, Cortex Magnoliae Officinalis 750 grams, Herba Ephedrae (processed) 380 grams.Above-mentioned single medicinal material extracts respectively, the united extraction composition, and behind the preparation micropill, encapsulated 1000.Rhizoma Dioscoreae Nipponicae is in diosgenin in the medicine of the present invention, and every is not less than 1.5mg; Cortex Magnoliae Officinalis is in magnolol and honokiol, and every contains magnolol (C18H1802) and honokiol (C18H1802) total amount should be not less than 6.0mg.
Embodiment 2: Rhizoma Dioscoreae Nipponicae 1300 weight portions, Herba Cymbopogonis 510 weight portions, Cortex Magnoliae Officinalis 750 weight portions.Above-mentioned single medicinal material extracts respectively, the united extraction composition, and behind the preparation micropill, encapsulated 1000.
Claims (6)
1, a kind of treatment bronchial asthma and acute and chronic bronchitic medicine is characterized in that this medicine is to be made by following crude drug: Rhizoma Dioscoreae Nipponicae 1000～2000 weight portions, Herba Cymbopogonis 1000～2000 weight portions, Cortex Magnoliae Officinalis 500～1500 weight portions.
2, medicine as claimed in claim 1 is characterized in that this medicine made by following crude drug: Rhizoma Dioscoreae Nipponicae 1300 weight portions, Herba Cymbopogonis 510 weight portions, Cortex Magnoliae Officinalis 750 weight portions.
3, a kind of treatment bronchial asthma and acute and chronic bronchitic medicine, it is characterized in that this medicine is to be made by following crude drug: Rhizoma Dioscoreae Nipponicae 1000～2000 weight portions, Herba Cymbopogonis 1000～2000 weight portions, Cortex Magnoliae Officinalis 500～1500 weight portions, Herba Ephedrae 200～600 weight portions.
4, medicine as claimed in claim 3 is characterized in that this medicine made by following crude drug: Rhizoma Dioscoreae Nipponicae 1300 weight portions, Herba Cymbopogonis 510 weight portions, Cortex Magnoliae Officinalis 750 weight portions, Herba Ephedrae 380 weight portions.
5, process for preparing medicine as claimed in claim 1 or 2 is characterized in that: single medicinal material is extracted respectively, and merge extractive liquid, is selected to optimize prepared and is become clinical acceptable pill, capsule, granule, tablet, oral liquid or injection etc.
6, use in preparation treatment bronchial asthma and acute and chronic bronchitis Chinese medicine as claim 1,2,3 or 4 described Chinese medicines.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN02130775.XA CN1218718C (en) | 2002-09-26 | 2002-09-26 | Medication for bronchial asthma and chronic bronchitis , and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN02130775.XA CN1218718C (en) | 2002-09-26 | 2002-09-26 | Medication for bronchial asthma and chronic bronchitis , and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1485056A true CN1485056A (en) | 2004-03-31 |
| CN1218718C CN1218718C (en) | 2005-09-14 |
Family
ID=34144610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN02130775.XA Expired - Fee Related CN1218718C (en) | 2002-09-26 | 2002-09-26 | Medication for bronchial asthma and chronic bronchitis , and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1218718C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100364587C (en) * | 2005-11-24 | 2008-01-30 | 徐磊 | Acupoint selection strapping medicine for treating chronic bronchitis and bronchial asthma and its compounding method |
| CN1985967B (en) * | 2006-12-15 | 2010-04-07 | 肖均 | Medicine for treating chronic bronchitis and bronchial asthma and its preparing method |
| CN101979085A (en) * | 2010-11-05 | 2011-02-23 | 刘志稳 | Medicament for treating cough and asthma diseases |
-
2002
- 2002-09-26 CN CN02130775.XA patent/CN1218718C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100364587C (en) * | 2005-11-24 | 2008-01-30 | 徐磊 | Acupoint selection strapping medicine for treating chronic bronchitis and bronchial asthma and its compounding method |
| CN1985967B (en) * | 2006-12-15 | 2010-04-07 | 肖均 | Medicine for treating chronic bronchitis and bronchial asthma and its preparing method |
| CN101979085A (en) * | 2010-11-05 | 2011-02-23 | 刘志稳 | Medicament for treating cough and asthma diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1218718C (en) | 2005-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1813868A (en) | Composition for treating and improving chronic fatigue syndrome and its preparing method | |
| CN1824185A (en) | Chinese medicinal composition for treating agrypnia, functional gastricism and astriction and its preparation method | |
| CN1775274A (en) | Cough-relieving sputum-resolving medicinal composition and preparing method | |
| CN1285358C (en) | Medicinal composition, preparation and quality control thereof | |
| CN1266693A (en) | Chinese medicinal composition for treating asthma and preparing process thereof | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN1660343A (en) | Combination of medication of containing eucalyptol, limonene and alpha pinene and application | |
| CN1485056A (en) | Medication for bronchial asthma and chronic bronchitis , and its preparation method | |
| CN1119107A (en) | Medicine for curing diseases of respiratory system, esp. bronchial asthma and preparing process thereof | |
| CN100341540C (en) | Angelica root mistletoe granules and its preparation method | |
| CN1136880C (en) | Combined Chinese and Western medicine for treating bronchial asthma | |
| CN1283300C (en) | Chinese traditional medicine composition for treating diabetes and preparation method thereof | |
| CN1175885C (en) | Zibei Cough stopping granules and its preparation method | |
| CN1202843C (en) | Drug rehabilitation oral liquid | |
| CN1264537C (en) | Capsule | |
| CN100337658C (en) | Chinese medicine composition for treating cold anemopyretic syndrome, and its preparing method | |
| CN1650903A (en) | Method of extracting roice clearing medicament from effective component in natural plant Chinese medicine | |
| CN1650895A (en) | Method of extracting medicamout having memory strengthening function from natural plant compound preparation | |
| CN1278734C (en) | Pharmaceutical composition for stopping drug addiction and its preparing process | |
| CN1211111C (en) | Antilipemic Chinese medicine | |
| CN1720906A (en) | Treatment asthma spray | |
| CN1772190A (en) | Medicine for treating chronic bronchitis | |
| CN1289139C (en) | Medicine for treating colitis and its preparing method | |
| CN1931256A (en) | Chinese medicine capsule for eliminating drug addiction and its prepn process | |
| CN1062766C (en) | Composition for health of smokers and preparing method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG HUAXIN PHARMACEUTICAL GROUP CORPORATION Free format text: FORMER OWNER: XI N XINGHUA PHARMACEUTICAL RESEARCH INSTITUTE Effective date: 20140618 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 710075 XI'AN, SHAANXI PROVINCE TO: 274000 HEZE, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140618 Address after: 274000 No. 48 Zhonghua West Road, Heze, Shandong Patentee after: SHANDONG HUAXIN PHARMACEUTICAL Group Corp. Address before: 710075 hi tech Road, No. 2, Xi'an hi tech Development Zone, Shaanxi, China. 22F Patentee before: XIAN XINGHUA MEDICINE INST |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050914 Termination date: 20210926 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |